Elevance Health

ELV.US Weekly Report · 2026-W29

Opening Summary

Elevance Health came under pressure this week following Q2 earnings that disappointed relative to expectations. While the company raised full-year EPS guidance to at least $27, second-quarter earnings per share and net profit both declined 13% and 16% year-over-year respectively, as market concerns over Medicaid membership losses and margin pressures overshadowed the guidance raise. By Friday’s close, the stock had fallen nearly 10% from the start of the week, with institutions maintaining a constructive stance while funds chose to exit, creating a tension between cheap valuation and weakening demand.

Price Action

ELV traded between 365.375 and 377.760 this week. Opening at 371.700 on Monday and closing at 373.110 on Friday represented a 0.07% increase from the prior week’s close of 372.850. This modest gain masks significant intra-week volatility: following earnings release, the stock declined to the weekly low of 365.375, representing a near-10% drawdown that reflected real-time market repricing of Medicaid risks. Weekly trading volume reached 1.94 million shares with turnover of $7.18 billion, a 0.9% turnover rate considered normal.

Valuation and Profitability

Current P/E stands at 16.33x, placing the stock at approximately the 23rd percentile within the 3-year range—a clear low position relative to the industry median of 35.39x. P/B ratio is 1.81x. TTM EPS is $22.85.

The Q2 2026 earnings report showed adjusted EPS of $7.45, declining 13.08% year-over-year, with revenue of $49.83 billion representing only 1.4% YoY growth—a marked deceleration. This contrasts sharply with consensus EPS estimates of $27.03 (median $26.98). The current TTM base of $22.85 falls significantly below consensus, implying the market harbors substantial expectations for second-half performance. Achieving the $27 full-year target would require approximately $4.15 in H2 EPS—a challenging task.

Q1 2026 EPS of $8.00 declined 6.25% sequentially and 16.75% year-over-year. Net profit of $1.463 billion in Q2 was down 16.06% YoY, while Q1’s $1.764 billion fell 19.19% YoY, showing consecutive quarterly profit deterioration.

Capital Flows

Capital flows turned negative this week. While mid-sized and retail investors showed some inflows ($1382.88 and $2473.42 respectively), outflows were larger ($1966.48 and $3840.75), with institutional capital directly net selling $495.16. Both institutional and retail participants across all size categories displayed net outflows, corresponding to the post-earnings stock decline.

Institutional Perspective

Among 22 covering institutions, 12 rate the stock “strong buy,” 2 “buy,” and 8 “hold,” with none rating it “sell.” The average price target is $449.09, implying 20.4% upside from the current $373.11 close. Targets range from $393 (floor) to $492 (ceiling), showing relatively dispersed views.

The most recent rating update occurred July 17, 2026, immediately following the earnings release. It should be noted that institutional ratings frequently lag behind both market repricing and capital flow signals.

Weekly Newsflow

Three primary news themes emerged:

1. Q2 Earnings Release and Guidance Raise (July 15): The company reported $49.83 billion in revenue (+0.8% YoY) and adjusted EPS of $7.45, but Medicaid membership losses and margin pressure sparked a negative market reaction with the stock plunging over 10%. Simultaneously, full-year EPS guidance was raised to at least $27, signaling company confidence in H2 performance.

2. Executive Buying Signal (July 18): CEO Gail Boudreaux purchased approximately $1 million in personal shares, signaling conviction in long-term company value.

3. Dividend Maintenance (July 17): The company announced a $1.72 per share dividend, preserving a high yield despite mounting profit pressure, raising questions about dividend sustainability.

Key news items (ranked by relevance):

• Elevance Health reports Q2 2026: Revenue $49.8B, Adj. diluted EPS $7.45, raises FY guidance
• Elevance Health Q2 FY26 adjusted EPS falls 15.7% to $7.45; revenue rises 0.8% to $49.83 billion
• Elevance beat earnings estimates, but the stock falls on Medicaid spending worries
• Elevance Health tumbles 9% during regular trading on membership decline
• Elevance Health (NYSE:ELV) Price Target Raised to $393.00
• ELV: Raised 2026 EPS guidance to at least $27.00 after strong Q2 performance and targeted investments
• Elevance Health CEO Gail Boudreaux acquires common shares worth $1,003,428.45
• Elevance Health declares USD 1.72 dividend per share
• Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
• BUZZ-Truist lifts US health insurer PTs on margin recovery prospects

Signal Conflict and Observation

This week presented clear signal contradictions: A low valuation (P/E at 23rd percentile) paired with broad institutional support (14 institutions buy-rated or higher) should theoretically attract capital inflows. Instead, capital exited and the stock fell sharply, indicating that market participants are repricing the company more pessimistically than institutions regarding near-term profit pressure and Medicaid risk. This divergence likely reflects:

1. Rating lag: Institutional ratings typically trail 1-2 weeks; this week’s ratings may not yet fully incorporate earnings disappointment;

2. Focal shift: Market attention has shifted from valuation cheapness to deteriorating profit trends, with near-term risk appetite receding;

3. Dividend sustainability: While the dividend is maintained, the declining profit backdrop raises implicit questions about the yield’s sustainability going forward.

The critical test for the second half is whether management can deliver on its $27 EPS guidance and whether Medicaid policy headwinds and membership losses stabilize. While current valuation appears compelling, it requires confirmation of an earnings bottom to constitute an attractive entry point.